BioWorld

May 29, 2009

Exelixis Shares Soar on $1B Cancer Drug Deal with Sanofi

If all goes according to plan, Exelixis Inc. could bank more than $1 billion under a new licensing and discovery deal with Sanofi-Aventis Group for phosphoinositide-3 kinase (PI3K) inhibitors targeting cancer. (BioWorld Today) Read More

Phase II Trial Update Triggers Wild Ride for Peregrine Shares

'Finished' Mouse Genome Is Still a Work in Progress

As Markets Brighten, Medivation Seeks $65.8M in Shares Offering

Neuropharm Revives Autism Drug, Rises on Partner Talks

Amylin 'Back to Business' Following Contentious Vote

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for May 13, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 12, 2026

Alzheimer’s, beyond the brain

BioWorld

Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...

Hantavirus zoonotic spillover illustration

First cruise ship hantavirus genome points to zoonotic spillover

BioWorld

The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...

Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

BioWorld

In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...